|
Regeneron,
AstraZeneca
Sign $120M mAB Agreement
February 5, 2007--Regeneron Pharmaceuticals has granted AstraZeneca a
non-exclusive license to use its VelocImmune
technology for the discovery of human monoclonal
antibodies. AstraZeneca will pay Regeneron $20
million up front and will make up to five additional
annual payments of $20 million, subject to the ability
to terminate the agreement after making the first
three additional payments. AstraZeneca will also
pay to Regeneron royalties on sales of any commercial
products resulting from use of the VelocImmune technology.
Regeneron
Pharmaceuticals
URL: http://www.pharmadd.com/topnews/February
5 2007_2.asp
|
